Empowering Leaders at the Global Pharma Executive Course: Navigating Industry Transformation

By João L. Carapinha

January 13, 2026

Global Pharma Executive Course

The fourth edition of the Global Pharma Executive Course runs from March to May 2026 at Portugal’s Faculdade de Medicina da Universidade Católica Portuguesa and Hospital da Luz Lisboa. The course targets pharma industry leaders, as rapid changes driven by tech advances, therapeutic innovation, and new market access models reshape the sector. The program offers practical, interactive training that covers key areas like R&D and supply chain, along with market access, business models, technology, future health trends, sustainability, and patient strategies. Renowned speakers from Pfizer and MSD join, as do those from Johnson & Johnson and Sanofi, while ViiV Healthcare, Roche, and Bluepharma participate too. GenH organizes it along with the Centro Académico Clínico Católica-Luz, fostering strategic leadership and networking as Portugal emerges as a European pharma hub.

The Global Pharma Executive Course stresses integrated leadership that bridges science, clinical practice, and industry, helping leaders navigate supply chain issues, handle digital innovation, and adopt patient-centric models. Portugal positions itself as a strategic player in European pharma education, where practical case studies and access from C-level executives at top firms highlight real-world skills. There’s value for professionals in health and pharma sciences, as well as management and law fields, while networks build around trends like sustainability and omnichannel strategies to stay ahead. After three editions, it has become a national reference that promotes competitiveness and improves long-term sector sustainability.

From a HEOR perspective, the program boosts leaders who integrate real-world evidence to aid market access and pricing, potentially leading to optimized value-based models and dropping drug lifecycle inefficiencies. Explore details at the Global Pharma Executive Course.

Reference url

Recent Posts

EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...
KEYTRUDA combination therapy
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer

By João L. Carapinha

June 26, 2026

The FDA has approved KEYTRUDA combination therapy with Trodelvy as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 at a Combined Positive Score of 10 or greater. This marks the first regulatory nod for a PD-...
cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...